Skip directly to page options Skip directly to A-Z link

Volume 11, Number 6—June 2005

Dispatch

Macrolide- and Telithromycin-resistant Streptococcus pyogenes, Belgium, 1999–20031

Surbhi Malhotra-Kumar*Comments to Author , Christine Lammens*, Sabine Chapelle*, Monique Wijdooghe*, Jasper Piessens*, Koen Van Herck*, and Herman Goossens*
Author affiliations: *University of Antwerp, Antwerp, Belgium

Main Article

Table A1

In vitro activity of 6 antimicrobial agents against macrolide-resistant Streptococcus pyogenes phenotypes during 1999–2003

Antimicrobial* Constitutive (n = 209)
 M (n = 279)
 Inducible (n = 18)
Range MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90
Erythromycin 4–>512 >512 >512 1–128 8 16 1–>512 4 >512
Clindamycin 2–>512 >512 >512 ≤0.03–4 0.06 1 0.125–256 0.75 128
Clarithromycin 1–>512 >512 >512 1–256 8 16 0.5–>512 2 >512
Azithromycin 4–>512 >512 >512 1–128 8 16 0.5–>512 4 >512
Tetracycline 0.06–128 32 64 ≤0.03–64 0.25 0.5 0.06–64 0.5 64
Telithromycin† 0.0075–32 1 8 0.0075–2 0.5 0.5 0.003–4 0.06 0.5

*Dilution range of 0.03 to 512 μg/mL for all antimicrobial agents except telithromycin, which is 0.00375 to 64 μg/mL.
†Breakpoints for telithromycin, susceptible ≤1μg/mL, resistant ≥4 μg/mL.

Main Article

1A preliminary account of this work was presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 30–November 2, 2004, Washington DC, USA.

Page created: April 24, 2012
Page updated: April 24, 2012
Page reviewed: April 24, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external